Basic Information
| LncRNA/CircRNA Name | PCAT7 |
| Synonyms | PCAT7, PCAN-R2 |
| Region | GRCh38_9:94555054-94603990 |
| Ensemble | ENSG00000231806 |
| Refseq | NR_121566 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | nasopharyngeal cancer |
| ICD-0-3 | C11 |
| Methods | qPCR, Western blot, Luciferase reporter assay |
| Sample | Nasopharyngeal Carcinoma cell lines (SUNE-1, CNE-1, HNE-1, CNE2, C666-1, HONE-1) |
| Expression Pattern | up-regulated |
| Function Description | Relative expression of PCAT7 expression in NPC cell lines and normal oral epidermal cell. Here, we discovered the novel LncRNA, prostate cancer associated transcript 7 (PCAT7), which was overexpressed and associated with worse prognosis in NPC. Decreased PCAT7 expression was found to significantly suppress tumor cell proliferation in vitro, and inhibited tumor growth and reduced the expression of proliferation antigen Ki67 in vivo. Rescue assay was performed to further confirm that PCAT7 contributed to the progression of NPC through regulating miR-134-5p/ELF2 signal pathway. .The Kaplan-Meier survival analysis indicated that PCAT7 high expression (red line, n=38) has a worse overall survival compared to the low expression subgroup (grey line, n=12)hese results indicated that PCAT7 might contribute to the tumor progression in NPC by functioning as a ceRNA to sponge miR-134-5p. |
| Pubmed ID | 28728844 |
| Year | 2017 |
| Title | Long non-coding RNA PCAT7 regulates ELF2 signaling through inhibition of miR-134-5p in nasopharyngeal carcinoma. |
External Links
| Links for PCAT7 | GenBank HGNC NONCODE |
| Links for nasopharyngeal cancer | OMIM COSMIC |